BioCryst Pharmaceuticals (BCRX) said Monday that interim trial data showed that an oral granule formulation of Orladeyo (berotralstat) demonstrated sustained reductions in monthly attack rates in pediatric patients aged 2 to less than 12 with hereditary angioedema.
After taking Orladeyo for one month, median and mean monthly attack rates dropped to 0 and 0.5 attacks per month, compared with 0.96 and 1.5 with standard-of-care, the biotechnology firm said.
The median attack rate remained at 0 through month 12, the company said, adding that Orladeyo's oral granule formulation was found to be safe and tolerated.
"We remain on track to submit our new drug application to the FDA this year," said Helen Thackray, chief research and development officer of BioCryst.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。